Miller-Fisher syndrome at King Chulalongkorn Memorial Hospital.
BACKGROUND
Miller-Fisher syndrome (MFS), a variant of Guillain-Barré syndrome (GBS) is a self-limiting demyelinating disease of the peripheral nervous system. Clinical spectrum, natural history, prognosis, and pathogenesis of MFS are not fully documented.


OBJECTIVE
Probe the clinical features of MFS in a tertiary center in Thailand and compare its pattern with other Asian countries.


METHODS
The clinical recordings were searched from databases at King Chulalongkorn Memorial Hospital (KCMH) between 2002 and 2007. Keywords were "Miller-Fisher syndrome" and "Guillain-Barré syndrome". Cases with MFS were recruited The data regarding clinical features, course, treatments, and investigations were reviewed. Comparisons with other large Asian series were demonstrated.


RESULTS
Six patients (male:female; 3:3) with MFS were analyzed The incident rate is 7.7% that of GBS. The median age was 54.3 years (range 28 to 73 years). MFS frequently started with diplopia followed by ophthalmoplegia and ataxia. Other clinical symptoms included limb dysesthesia and weakness, dysphagia, dysarthria, and diffuse headache. Spontaneous recovery occurred in three patients while two patients received plasmapheresis and one received intravenous immunoglobulin (IVIG). Six months after neurological deficits, all patients were almost free of symptoms and had returned to their normal activities.


CONCLUSIONS
The incidence, clinical features, and prognosis of MFS in KCMH were comparable with the previous studies in other Asian countries. High percentage of limb dysesthesia and optic neuropathy were detected in the present series. Headache was also common among Thai MFS. Immuno-pathogenesis of MFS is well documented but immunomodulatory therapy should be considered only in some cases.
Lolekha
Praween
P
Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Thammasart University Hospital, Pathum Thani, Thailand.
Phanthumchinda
Kammant
K
D000328:Adult; D000368:Aged; D044466:Asian People; D001259:Ataxia / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D008875:Middle Aged; D019846:Miller Fisher Syndrome / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D009886:Ophthalmoplegia / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D010956:Plasmapheresis; D011379:Prognosis; D013785:Thailand
D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors